Eisai Co., Ltd.: Phase 2 study closed enrollment, 125 enrolled (Solid Neoplasms)
Eisai Co., Ltd.: Phase 2 study closed enrollment, 125 enrolled (Solid Neoplasms). Its enrollment of 125 is above the median of 80 (66th percentile). Dated 23 days ago, it is in the active follow-up window. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 125 · 66th percentile of 8,879 ClinicalTrialStartPulse records · 1.6x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Eisai Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor |
| NCT ID | NCT04078295 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Solid Neoplasms |
| Intervention types | drug |
| Target enrollment | 125 |
| Site countries | Japan |
| Posted | 2019-09-06 |
| Planned start | 2019-09-05 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |
| enrollment percentile | 66th of 8,879 (median 80, 1.6x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Eisai Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Eisai Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-13
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Eisai Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Eisai Co., Ltd.'s enrollment: 66th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 125 participants planned.
What is the ClinicalTrialStartPulse record for Eisai Co., Ltd.?
Eisai Co., Ltd.'s Phase 2 study (NCT04078295) in Solid Neoplasms, first posted 2019-09-06: enrollment closed (active, not recruiting) (2026-10-13), in an update posted 2026-10-13.
How does Eisai Co., Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 125 sits in the upper half (66th percentile) of 8,879 records; the median is 80. It is 23 days old, still within a typical 45-day follow-up window. Its Score of 75/100 puts it among the stronger signals in this feed.
Eisai Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Eisai Co., Ltd. | NONUS | 125 | 66th | 2026-10-13 |
| Nurix Therapeutics, Inc. | US | 150 | 71st | 2026-11-03 |
| BeOne Medicines | NONUS | 100 | 60th | 2026-11-03 |
| Janssen Research & Development, LLC | US | 166 | 73rd | 2026-11-03 |
Related records
- Nurix Therapeutics, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Apogee Therapeutics, Inc.
- Janssen Research & Development, LLC
- BeOne Medicines
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor Eisai Co., Ltd. and peer phase 2 records
Get new ClinicalTrialStartPulse records like Eisai Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.